Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-Escalation, Non-comparative Clinical Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-245 (JSC BIOCAD, Russia) Administered Intravenously to Subjects With Neuroblastoma

NCT05782959 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT05782959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05782959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-Escalation, Non-comparative Clinical Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-245 (JSC BIOCAD, Russia) Administered Intravenously to Subjects With Neuroblastoma
Lead sponsor
Biocad
Phase
Phase 1
Overall status
Unknown status
Start date
November 29, 2021
Completion date
June 30, 2023
Enrollment
24 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma